DIACEUTICS PLC |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 127.3 GBX | -0.19% |
|
+15.69% | +46.28% |
| May. 21 | EARNINGS AND TRADING: Topps Tiles in strategic shift as swings to loss | AN |
| May. 21 | Transcript : Diaceutics PLC, 2023 Earnings Call, May 21, 2024 |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company's earnings growth outlook lacks momentum and is a weakness.
- Low profitability weakens the company.
- The company's enterprise value to sales, at 3.85 times its current sales, is high.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
Ratings chart - Surperformance
Sector: Business Support Services
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +46.28% | 137M | - | ||
| +18.54% | 4.55B | D+ | ||
| -17.69% | 2.36B | - | ||
| +33.77% | 2.06B | B- | ||
| -7.59% | 1.63B | - | ||
| +3.13% | 1.59B | - | B- | |
| -18.98% | 1.54B | D- | ||
| -33.24% | 1.17B | - | ||
| -8.07% | 1.16B | - | ||
| -7.40% | 1.02B | - | - |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
- Stock Market
- Equities
- DXRX Stock
- Ratings Diaceutics PLC
